Literature DB >> 24144240

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Yunyun Yuan1, Saheem A Zaidi, Orgil Elbegdorj, Lindsey C K Aschenbach, Guo Li, David L Stevens, Krista L Scoggins, William L Dewey, Dana E Selley, Yan Zhang.   

Abstract

On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. The first-generation ligands appeared to be MOR-selective, whereas the second and the third generation ones showed MOR/kappa opioid receptor (KOR) dual selectivity. Docking of ligands 2 (MOR selective) and 10 (MOR/KOR dual selective) to the three opioid receptor crystal structures revealed a nonconserved-residue-facilitated hydrogen-bonding network that could be responsible for their distinctive selectivity profiles. The MOR/KOR dual-selective ligand 10 showed no agonism and acted as a potent antagonist in the tail-flick assay. It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent mice. In conclusion, ligand 10 may serve as a novel lead compound to develop MOR/KOR dual-selective ligands, which might possess unique therapeutic value for opioid addiction treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24144240      PMCID: PMC4373589          DOI: 10.1021/jm4012214

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  52 in total

1.  The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.

Authors:  M Tsuji; H Takeda; T Matsumiya; H Nagase; M Narita; T Suzuki
Journal:  Life Sci       Date:  2001-03-02       Impact factor: 5.037

Review 2.  Enzymatic synthesis of optically active tertiary alcohols: expanding the biocatalysis toolbox.

Authors:  Robert Kourist; Pablo Domínguez de María; Uwe T Bornscheuer
Journal:  Chembiochem       Date:  2008-03-03       Impact factor: 3.164

3.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

4.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

Review 5.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 6.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

7.  Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.

Authors:  S N Calderon; R B Rothman; F Porreca; J L Flippen-Anderson; R W McNutt; H Xu; L E Smith; E J Bilsky; P Davis; K C Rice
Journal:  J Med Chem       Date:  1994-07-08       Impact factor: 7.446

8.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

9.  Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release.

Authors:  R Spanagel; O F Almeida; C Bartl; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

10.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

View more
  7 in total

1.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

2.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

3.  Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.

Authors:  Boshi Huang; Rama Gunta; Huiqun Wang; Mengchu Li; Danni Cao; Rolando E Mendez; James C Gillespie; Chongguang Chen; Lan-Hsuan M Huang; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  Bioorg Chem       Date:  2021-02-09       Impact factor: 5.275

4.  Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.

Authors:  Rajendra Uprety; Tao Che; Saheem A Zaidi; Steven G Grinnell; Balázs R Varga; Abdelfattah Faouzi; Samuel T Slocum; Abdullah Allaoa; András Varadi; Melissa Nelson; Sarah M Bernhard; Elizaveta Kulko; Valerie Le Rouzic; Shainnel O Eans; Chloe A Simons; Amanda Hunkele; Joan Subrath; Ying Xian Pan; Jonathan A Javitch; Jay P McLaughlin; Bryan L Roth; Gavril W Pasternak; Vsevolod Katritch; Susruta Majumdar
Journal:  Elife       Date:  2021-02-08       Impact factor: 8.140

5.  Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.

Authors:  Hongguang Ma; Huiqun Wang; James C Gillespie; Rolando E Mendez; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2021-03-22       Impact factor: 2.940

6.  Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation.

Authors:  Eelke B Lenselink; Julien Louvel; Anna F Forti; Jacobus P D van Veldhoven; Henk de Vries; Thea Mulder-Krieger; Fiona M McRobb; Ana Negri; Joseph Goose; Robert Abel; Herman W T van Vlijmen; Lingle Wang; Edward Harder; Woody Sherman; Adriaan P IJzerman; Thijs Beuming
Journal:  ACS Omega       Date:  2016-08-30

7.  Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses.

Authors:  Martiniano Bello
Journal:  Molecules       Date:  2022-08-02       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.